Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ann & Robert H Lurie Children's Hospital of Chicago
Age
3–21
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must be \>/= 3 and \</= 21 years of age.
Patients must have a newly diagnosed or progressive brain stem tumor.
If biopsy has been performed, patients with both high and low grade astrocytomas are eligible.
Non-histologically confirmed brain stem tumors are eligible. Neuroradiographic confirmation of brain stem glioma is mandatory for study entry.
Cervicomedullary junction tumors are ineligible.
Patients with a diagnosis of NF-1 are ineligible.
Patients must be registered within 6 weeks from diagnosis or recurrence.
Patients must have life expectancy \> 6 weeks.
Patients must have adequate hematologic and renal function: ANC \>1,000/ul, platelets\>100,000/ul and creatinine normal for age: \</= 0.7 mg/dl (age 3-10yrs.), \</= 1.0 mg/dl (11-12yrs.). and \</= 1.2 (13-21yrs.).
Written informed consent must be obtained according to institutional guidelines.
Pregnant or nursing women are ineligible.
Patients must be registered within 3 days prior to the start of protocol treatment. Patients must not start treatment until informed consent is given and the patient is registered. Willingness and ability to comply with the FDA-mandated S.T.E.P.S.® program.
Clareo Health | Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
